Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

BACKGROUND: Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed diabetic drugs that primarily work on the kidney. Clinical data describing the...

詳細記述

保存先:
書誌詳細
出版年:Cardiovasc Diabetol
主要な著者: Arow, M., Waldman, M., Yadin, D., Nudelman, V., Shainberg, A., Abraham, N. G., Freimark, D., Kornowski, R., Aravot, D., Hochhauser, E., Arad, M.
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2020
主題:
Original Investigation
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6953156/
https://ncbi.nlm.nih.gov/pubmed/31924211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0980-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料